Aurinia Pharmaceuticals earnings release, August 6, 2026

Aurinia Pharmaceuticals Inc. (AUPH) · Form 8-K, Item 2.02 · Filed · SEC filing

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Maryland and EDMONTON, Alberta – August 6, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six months ended June 30, 2026 and provided an update on recent business progress.

Financial Results

• Total Revenue:

For the three and six months ended June 30, 2026, total revenue was $83.2 million and $160.9 million, up 19% and 21%, respectively, from $70.0 million and $132.5 million, respectively, in the same periods of 2025. – Net Product Sales:

For the three and six months ended June 30, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $79.4 million and $153.0 million, up 19% and 21%, respectively, from $66.6 million and $126.5 million, respectively, in the same periods of 2025. – License, Collaboration and Royalty Revenue:

For the three and six months ended June 30, 2026, license, collaboration and royalty revenue was $3.8 million and $8.0 million, up 12% and 36%, respectively, from $3.4 million and $5.9 million, respectively, in the same periods of 2025.

• Net Income:

For the three and six months ended June 30, 2026, net income was $37.4 million and $71.8 million, up 74% and 60%, respectively, from $21.5 million and $44.9 million, respectively, in the same periods of 2025.

• Diluted Earnings per Share:

For the three and six months ended June 30, 2026, diluted earnings per share was $0.28 and $0.53, up 75% and 66%, respectively, from $0.16 and $0.32 in the same periods of 2025.

• Cash Flows from Operating Activities:

For the three and six months ended June 30, 2026, cash flows from operating activities were $52.5 million and $85.1 million, up 19% and 87%, respectively, from $44.2 million and $45.5 million in the same periods of 2025.

Cash Position

As of June 30, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $443.1 million, compared to $398.0 million at December 31, 2025. For the six months ended June 30, 2026, cash outflows from financing activities were $48.9 million, which included the repurchase of 5.0 million of the Company’s common shares for $74.9 million, partially offset by proceeds from issuance of common shares for equity awards, net of tax withholding payments, of $32.7 million.

2026 Total Revenue and Net Product Sales Guidance

Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net product sales of $305 million to $315 million, up 12% to 16% compared to 2025.

Recent Development Progress

LUPKYNIS

Aurinia has recently initiated PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis. Belimumab is a B cell-activating factor (BAFF) inhibitor indicated for the treatment of both systemic lupus erythematosus (SLE) and lupus nephritis. Obinutuzumab is a CD20-directed cytolytic antibody indicated for the treatment of lupus nephritis. Anifrolumab is a type 1 interferon receptor antagonist indicated for the treatment of SLE. PRESERVE will investigate whether the¹ multi-target approach of combining LUPKYNIS with these biologic agents improves outcomes in patients with lupus nephritis. Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study’s primary endpoint is the proportion of patients achieving complete renal response (CRR) at 6 months.

Aritinercept

Aritinercept is a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Aurinia has now initiated clinical development of aritinercept in four potential indications.

About Aurinia

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS®

(voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.

Financial statements

Income Statement

Three Months Ended — (in thousands, except per share data)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
RevenueNet product sales79,41266,574152,975126,545
RevenueLicense, collaboration and royalty revenue3,8083,4347,9505,928
RevenueTotal revenue83,22070,008160,925132,473
Operating expensesCost of revenue6,5557,11513,06015,689
Operating expensesSelling, general and administrative23,50826,01845,53746,357
Operating expensesResearch and development13,0507,43220,52013,175
Operating expensesRestructuring1141,647
Operating expensesOther (income) expense, net-6,2349,246-5,95513,675
Operating expensesTotal operating expenses36,87949,92573,16290,543
Operating expensesIncome from operations46,34120,08387,76341,930
Operating expensesInterest income3,3933,1906,9086,759
Operating expensesInterest expense-948-1,117-1,960-2,184
Operating expensesNet income before income taxes48,78622,15692,71146,505
Operating expensesIncome tax expense11,37264320,9421,648
Operating expensesNet income37,41421,51371,76944,857
Earnings per shareBasic0.290.160.550.33
Earnings per shareDiluted0.280.160.530.32
Shares used in computing earnings per shareBasic130,081134,873131,221136,878
Shares used in computing earnings per shareDiluted133,530137,526135,518140,193

Balance Sheet

(in thousands)

June 30, 2026 – (Unaudited)December 31, 2025
Current assets:Cash, cash equivalents and restricted cash179,83280,213
Current assets:Short-term investments263,291317,784
Current assets:Accounts receivable, net41,13841,454
Current assets:Inventory45,15145,690
Current assets:Prepaid expenses and deposits10,5315,746
Current assets:Other current assets1,3811,080
Current assets:Total current assets541,324491,967
Current assets:Deferred tax assets, net178,935176,194
Current assets:Finance right-of-use lease assets65,15273,865
Current assets:Intangible assets, net3,3783,761
Current assets:Operating right-of-use lease assets1,5183,596
Current assets:Property and equipment, net1,8622,111
Current assets:Other noncurrent assets9393
Current assets:Total assets792,262751,587
Current liabilities:Accounts payable1,7353,313
Current liabilities:Accrued expenses64,11266,621
Current liabilities:Finance lease liabilities, current portion16,47916,523
Current liabilities:Deferred revenue10,5933,720
Current liabilities:Operating lease liabilities, current portion1,7051,067
Current liabilities:Other current liabilities5,2692,480
Current liabilities:Total current liabilities99,89393,724
Current liabilities:Finance lease liabilities, less current portion43,94352,322
Current liabilities:Deferred tax benefits23,128
Current liabilities:Deferred revenue, less current portion7,48012,648
Current liabilities:Operating lease liabilities, less current portion2,0094,900
Current liabilities:Other noncurrent liabilities9456,662
Current liabilities:Total liabilities177,398170,256
Shareholders' equityCommon shares — no par value, unlimited shares authorized, 132,907 and 132,323 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1,117,2481,120,035
Shareholders' equityAdditional paid-in capital76,192111,263
Shareholders' equityAccumulated other comprehensive loss-977-599
Shareholders' equityAccumulated deficit-577,599-649,368
Shareholders' equityTotal shareholders' equity614,864581,331
Shareholders' equityTotal liabilities and shareholders' equity792,262751,587

Cash Flow

Six Months Ended June 30, — (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activities:Net income71,76944,857
Adjustments to reconcile net income to cash flows from operating activities:Deferred income tax20,387
Adjustments to reconcile net income to cash flows from operating activities:Share-based compensation1,9732,031
Adjustments to reconcile net income to cash flows from operating activities:Amortization and depreciation9,6509,720
Adjustments to reconcile net income to cash flows from operating activities:Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability-9779,265
Adjustments to reconcile net income to cash flows from operating activities:Net amortization of premiums and discounts on investments-4,200-5,219
Adjustments to reconcile net income to cash flows from operating activities:Other, net-2,0824,132
Net changes in operating assets and liabilities:Accounts receivable, net316-3,547
Net changes in operating assets and liabilities:Inventory539-7,275
Net changes in operating assets and liabilities:Prepaid expenses and other current assets-5,0315,106
Net changes in operating assets and liabilities:Other noncurrent operating assets730
Net changes in operating assets and liabilities:Accounts payable-3,451-1,875
Net changes in operating assets and liabilities:Accrued expenses and other liabilities-5,031-17,136
Net changes in operating assets and liabilities:Deferred revenue1,7055,147
Net changes in operating assets and liabilities:Operating lease liabilities-441-395
Net changes in operating assets and liabilities:Cash flows from operating activities85,12645,541
Full release

Forward-Looking Statements

This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com.

Investor Inquiries ir@auriniapharma.com²

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Aurinia Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.